Sequoia Capital Israel

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Cloudphysician is a prominent provider of Smart-ICU services that utilizes a cloud-based platform to enhance critical care delivery. The company employs advanced technologies, including artificial intelligence, the Internet of Things, and predictive analytics, to facilitate real-time clinical decision-making and improve patient outcomes. By offering remote management solutions, Cloudphysician enables healthcare providers to monitor patients effectively, assisting in early-stage diagnosis of critical illnesses in adults and tracking the health and immunization of newborns to reduce neonatal mortality rates. Through this innovative approach, Cloudphysician aims to transform the healthcare landscape, providing hospitals and healthcare professionals with improved support and training capabilities.

Black Jade Star Rock develops organoid-based intelligent equipment and chips. It is a biomedical research and development company with organoid science as its fundamental technology.

Generation Lab aims to enhance human health by developing the first clinically applicable test that assesses an individual's biological age progression and disease risk. This enables longer, healthier lives.

Spear Bio is a biotechnology company based in Weston, Massachusetts, founded in 2021. The company specializes in ultrasensitive protein detection technology, which significantly enhances healthcare diagnostics. Its innovative approach enables the quantification of minute protein biomarkers from samples collected at home, facilitating self-testing and telemedicine applications. By allowing clinicians to detect these biomarkers from small sample volumes, Spear Bio's technology integrates seamlessly into existing workflows for sample collection, processing, and detection, thereby improving the overall efficiency of healthcare delivery.

FUE Bioscience is a medical robot R&D business that specializes in microsurgery above the head and neck. It continues to develop a product matrix of fully intelligent, high-precision, and anthropomorphic surgical robots based on the platform of macro-micro-controlled humanoid dual-arm robots.

Neurowyzr is a company focused on enhancing brain health through a comprehensive healthcare platform. It specializes in the detection, diagnosis, therapy, monitoring, and prevention of brain decline. By offering a range of evidence-based tools, Neurowyzr empowers healthcare providers to promote awareness and facilitate positive changes in brain health. The company's approach emphasizes early intervention and the prevention of cognitive decline, aiming to shift societal perspectives on brain health and encourage proactive maintenance of cognitive well-being.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Meichuang Medical is an innovative medical device company that focuses on the R&D, manufacturing and commercialization of high-end medical devices in the fields of peripheral vascular intervention, tumor intervention, and hemodialysis access maintenance

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

HealiRNA develops infectious disease vaccines, tumor vaccines, cell therapy, and protein replacement. They provide mRNA drug research and development, production, clinical trial design, and data analysis services.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

NeuroXess is a high-tech life science company focusing on flexible electrode BCI (Brain-computer interface) technologies to protect and explore the brain.

GenAssist Therapeutics, founded in July 2020 by a team of leading scientists and industry experts, specializes in the development of gene therapy drugs utilizing advanced base editing technology. The company is focused on addressing neuromuscular diseases that currently lack effective treatments, particularly Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). GenAssist aims to provide permanent cures by precisely repairing disease-causing genes directly within patients' cells. The company holds global intellectual property rights to its proprietary Targeted AID-based Mutagenesis (TAM) technology, positioning it at the forefront of innovative solutions for a range of genetic disorders.

Insight Lifetech is a medical technology company focused on developing and manufacturing innovative solutions for the diagnosis and treatment of cardiovascular diseases. The company has established a comprehensive platform that integrates research and development, manufacturing, and commercialization, facilitating collaboration across its operations. This synergy accelerates product development, enhances cost-efficiency, and fosters innovation. Notably, Insight Lifetech developed the first domestic fractional flow reserve (FFR) system in China, which received approval from the National Medical Products Administration. Through its high-quality medical devices and advanced technologies, the company aims to provide reliable precision in cardiovascular diagnosis and therapy, ultimately enabling physicians to save and improve patients' lives.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

WuXi Bo Rui Biotechnology develops a radioactive molecular imaging and nuclear drug transformation platform for the precise diagnosis and treatment of tumors. WuXi Bo Rui Biotechnology focuses on the transformation and development of new radionuclide drugs, covering multiple fields of small molecules, peptides, and antibodies, for the diagnosis and treatment of tumors, using their professional platform for targeted precursor design, screening, and radionuclide labeling. While increasing the efficiency of research and development, it also fully utilizes the benefits of accurate nuclear medicine diagnosis and treatment

DigitAlp is a scientific and technical innovation company focused on enhancing the value of clinical research through digital solutions. The company offers an integrated platform that supports the entire clinical trial process, centered around institutions. Their solution comprises four key modules: an institutional comprehensive management system, a trial electronic medical record system, a sponsor service system, and a subject recruitment and full-service system. These modules enable efficient management for various parties involved in clinical research.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

Hao Microbiology is a developer of vascular interventional embolization products.

CureFun is an online education portal that specializes in medical education services. The company offers a comprehensive range of training process management services, including online theoretical learning, self-assessment, and examination services. It also provides a question bank with intelligent wrong question recommendation training to enhance learning outcomes. Additionally, CureFun has developed a clinical diagnosis and treatment simulation platform that allows medical students to engage in realistic simulations of clinical scenarios. This interactive virtual practice enables students to develop their clinical thinking skills, accumulate knowledge, and gain valuable experience in a controlled environment. Through its diverse offerings, CureFun aims to enhance the educational experience for medical professionals in training.

XiSoft is a professional manufacturer specializing in informatization and data services within the health economic management sector. The company focuses on leveraging technology and services to support medical institutions by offering a smart operations management tool. This platform covers various aspects including intelligent finance, material assets, internal control, human resources, comprehensive management, event management, data services, and information platforms. XiSoft's solutions aim to facilitate the strategic implementation of medical institutions, enabling business integration and refined management.

Grit Science is a biotechnology company specializing in gene therapeutics, focusing on the research and development of liver-related genetic treatments. The firm is dedicated to creating innovative medical products that address clinical needs and enhance human health. Through its commitment to advancing biopharmaceutical technology, Grit Science aims to provide effective solutions in the field of genetic medicine.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

HemaCell is a biotechnology company specializing in cell therapy, specifically focused on regenerating hematopoietic lineages, which include blood and immune cells, through advanced in vitro techniques. Leveraging innovative stem cell reprogramming, editing, and differentiation technologies, HemaCell aims to address the critical shortage of platelets necessary for treating various diseases such as cancer, liver disease, critical illness, and hematological disorders. The company employs a unique platform that utilizes platelets as drug delivery carriers, facilitating the rapid establishment of induced pluripotent stem cells (iPSCs) and gene targeting technologies. In addition to platelet production, HemaCell is dedicated to developing novel therapeutic solutions for diseases associated with platelet abnormalities, thereby offering effective treatment options and addressing significant medical needs.

SceneRay Co. Ltd, based in Singapore Industrial Park in Suzhou, China, is a medical device company specializing in the design, development, and distribution of neuromodulation devices. The company focuses on creating advanced medical products, including a dual-channel implantable pulse generator kit for deep brain stimulation. This technology is designed to provide effective treatments for patients suffering from brain damage through electric stimulation. SceneRay's core team comprises experts with extensive experience in neuromodulation device development, manufacturing, and marketing, both in China and internationally. The company holds numerous patents and is committed to exploring innovative solutions in the field of neuromodulation, aiming to deliver high-quality and effective treatments to improve patient outcomes.

Sirka is Indonesia's first metabolic clinic, specializing in healthcare innovation with a focus on obesity and metabolic health. The company adopts a tech-enabled, holistic approach to managing weight and chronic diseases, addressing the root causes of these issues. Sirka offers personalized programs that encompass weight management, digestive health, diabetes care, and chronic disease management. Through expert medical care and customized nutrition plans, the clinic tailors its services to meet individual needs while providing continuous monitoring to ensure effective support for long-term success. Additionally, Sirka's application connects users with dietitians for meal plan recommendations, facilitating goal setting related to diet and health conditions. This comprehensive approach empowers Indonesians to lead healthier lives with improved weight management and better control over chronic diseases.

the first high-tech company in China to focus on the treatment of cerebrovascular disease, it has more than four years of product research and development, leading China's cerebrovascular disease intelligence in an all-around way. vertical field of diagnosis and treatment. It has become a well-known brain stroke intelligence diagnosis and treatment platform in China.

Tongxin makes magnetically-suspended artificial blood pumps which are designed to replace the human heart. They are undergoing clinical trials in China after being fast-tracked through the approval process by the National Medical Products Administration, state-run Xinhua News Agency

Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects to continuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization. It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.

NeuroXess is a high-tech life science company focusing on flexible electrode BCI (Brain-computer interface) technologies to protect and explore the brain.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Vico Medical, established in 2018 and based in Wuhan, China, specializes in the development and production of medical devices aimed at treating cardiovascular and cerebrovascular diseases. The company offers a range of products, including atrial shunts, puncture systems, and occluders for patent foramen ovale, along with delivery systems and other related devices. Vico Medical focuses on providing innovative intervention treatment solutions for structural cardiovascular issues, contributing to the reduction of stroke and heart-related disease incidents.

Dangsheng New Material is a high-performance fiber material developer and a high-tech enterprise dedicated to the development, production and sales of high-performance fiber materials. It has realized the production of China's only high-performance anti-virus and biochemical barrier protective clothing made of a single material. . Dangsheng New Materials provides a series of medical disposable protective products, including protective clothing, isolation clothing, protective shoe covers and other supplies.

Pristyn Care is a healthcare startup focused on transforming day care procedures through advanced surgical care and innovative techniques. Founded by former consultant surgeons from prestigious institutions, along with professionals from the technology and business sectors, the company aims to enhance patient outcomes and streamline the surgical experience. Pristyn Care specializes in advanced laser surgeries across various medical fields, including urology, proctology, ENT, gynecology, laparoscopy, and dermatology. By leveraging cutting-edge technology and implementing efficient operational processes, Pristyn Care seeks to create a comprehensive ecosystem that organizes and optimizes day care procedures, ultimately improving recovery times and overall health for patients.

Shanghai Duoning Biotechnology Co., Ltd. specializes in the development of serum-free, personalized, and chemically defined cell culture media for the biopharmaceutical industry. Founded in 2005 and based in Shanghai, the company offers a range of products, including basic media, feed media, and cell therapy media. Duoning Biotech is dedicated to providing tailored media development, cell culture process optimization, and commissioned formula production services, utilizing its expertise in animal cell culture concepts. The company supports the research, development, and commercialization of biologics products by delivering comprehensive solutions that encompass technical support and customized services tailored to the needs of pharmaceutical and scientific research institutions.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

BDG is a specialist hospital focusing on the diagnosis and treatment of brain diseases, brain health management, and brain neurology research.

ComGen Pharma is a biotechnology company that specializes in the research and development of innovative therapeutic drugs targeting the complement system. The company aims to create effective immunotherapies for autoimmune diseases and tumors by focusing on new and key targets within this biological pathway. Recently, ComGen Pharma secured nearly 100 million yuan in financing, which will primarily support phase I clinical trials for its complement inhibitors, advance its drug pipeline, and enhance its innovative drug research and development platform. The financing round was led by prominent investors, including Sequoia China and Yahui Investment, with additional support from Fuchuang Investment and Renyou Investment.

Mosaic Wellness is a platform of digital-first health clinics and wellness brands operating in India under a single umbrella. It provides medical consultations, personalized wellness assessments, and a range of wellness products through its digital platform, with specialized offerings for men's and women's health. By linking multiple digital health brands, Mosaic Wellness seeks to help individuals lead healthier, more fulfilling lives through accessible, tailored care and products.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Cellular Biomedicine Group, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company employs proprietary cell-based technologies, including various forms of CAR-T therapy, which targets different cancer types, and human adipose-derived mesenchymal progenitor cells aimed at treating joint diseases. Its product pipeline features therapies such as CD20 and CD22 CAR-T for B cell malignancies, and alpha fetoprotein TCR-T targeting hepatocellular carcinoma. Additionally, Cellular Biomedicine is developing knee osteoarthritis treatments, including AlloJoin and Re-Join, the latter having completed Phase IIb trials. The company also engages in broader biopharmaceutical activities, encompassing research and development, technical support, and manufacturing of pharmaceutical polypeptides and medical devices. It has established a partnership with Novartis Pharma AG to produce and supply the CAR-T cell therapy Kymriah in China. Founded in 2001, Cellular Biomedicine Group is headquartered in New York, New York, and draws on a wealth of cellular medicine research and expertise from scientists and clinicians across the United States, England, and China.

Metware is a developer of advanced medical metabolic technology, focusing on metabolomics to enhance life science research and clinical applications. The company specializes in metabolism analysis and testing services, targeting areas such as cancer, metabolic disorders, and infectious diseases. By leveraging innovative metabolism technology, Metware aims to provide effective data analysis that supports patients and facilitates improved treatment options in the medical field.

Yixue Jie is an app that offers medical information to medical workers. They provide information in these categories such as grassroots medical voice in the medical field, medical tumor channel, medical rheumatology and immunity channel, medical skin channel, medical cardiovascular channel, medical endocrinology channel, medical neurology channel, medical blood channel, medical pediatric channel, medical obstetrics and gynecology channel, medical respiratory channel, medical nephrology channel, digestive liver disease channel in medical circles, clinical pharmacy channel of the medical community, medical rare disease channel, medical cancer association, medical emergency and critical care channel, medical spirit channel, medical surgical channel, medical nursing channel, medical ophthalmology channel, medical infection channel, medical anesthesia channel, medical orthopedics channel, medical testing channel, medical image diagnosis and intervention channel, medical pathology channel, clinical decision assistant, a course in the medical field, and medical examination. It helps clinicians in clinical decision-making and professional advancement.

Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.

Yuanxin Huibao is a health insurance technology service provider that specializes in medical insurance for major and chronic diseases. The company focuses on enhancing user experiences by offering comprehensive medical coverage, which includes features such as special drug services, video consultations, welfare drugs, and claims investigations. By integrating these services, Yuanxin Huibao aims to deliver more reliable medical solutions to its users while also providing insurance companies with a one-stop solution for risk control, pricing, and user acquisition.

Shanghai Anovent Pharmaceutical Co., Ltd., founded in 2017 and headquartered in Shanghai, China, specializes in the development of high-quality inhalation medicines tailored for hospitals and medical institutions. The company focuses on offering safe and affordable pharmaceutical products, which include both generic and specialized inhalation therapies. By providing these medications, Anovent aims to enhance the quality of medical treatment available to patients in healthcare settings.

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in developing innovative cell therapies aimed at treating a range of human diseases, including cancer, rare disorders, and immunological and metabolic conditions. Central to its approach is the REDx platform, which enables the engineering of red blood cells and utilizes genetic modifications of hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood. This technology facilitates the creation of personalized treatment solutions, enhancing the potential for effective therapies tailored to individual patient needs.

ProfoundBio is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics with curative potential for cancer, including antibody-drug conjugate candidates targeting solid tumors and hematologic malignancies that are in discovery, preclinical, and clinical development, with programs designed to leverage the immune system to eradicate cancer through targeted therapeutics.

XiSoft is a professional manufacturer specializing in informatization and data services within the health economic management sector. The company focuses on leveraging technology and services to support medical institutions by offering a smart operations management tool. This platform covers various aspects including intelligent finance, material assets, internal control, human resources, comprehensive management, event management, data services, and information platforms. XiSoft's solutions aim to facilitate the strategic implementation of medical institutions, enabling business integration and refined management.

Phanes Therapeutics is a biotechnology company specializing in drug discovery for immuno-oncology and eye diseases. Established in 2016, the company focuses on developing monoclonal antibodies for solid tumors and conditions like age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, they work on bispecific antibodies targeting small cell lung cancer.

Valgen focus on treatment technologies and systemic solutions for heart disease, especially for mitral and tricuspid valve lesions.

VivaVision Biotech is a clinical-stage R&D biopharmaceutical company that is developing novel medicines to treat topical diseases. VivaVision Biotech is dedicated to bringing new therapeutics to millions of patients suffering from chronic ocular or dermal inflammatory diseases.

Pristyn Care is a healthcare startup focused on transforming day care procedures through advanced surgical care and innovative techniques. Founded by former consultant surgeons from prestigious institutions, along with professionals from the technology and business sectors, the company aims to enhance patient outcomes and streamline the surgical experience. Pristyn Care specializes in advanced laser surgeries across various medical fields, including urology, proctology, ENT, gynecology, laparoscopy, and dermatology. By leveraging cutting-edge technology and implementing efficient operational processes, Pristyn Care seeks to create a comprehensive ecosystem that organizes and optimizes day care procedures, ultimately improving recovery times and overall health for patients.

Connect Medical Value Technology is a company established in 2020 and based in Hangzhou, Zhejiang, China. It specializes in developing mobile applications designed for physicians, offering a comprehensive platform that integrates clinical services, scientific research, and educational resources. The company's applications leverage advanced artificial intelligence technology to enhance medical practice and improve healthcare delivery. Through its innovative solutions, Connect Medical Value aims to support healthcare professionals in their clinical decision-making and ongoing education.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

WeDoctor is a prominent medical health technology platform founded in 2010 by Liao Jieyuan and his team. The company aims to enhance access to healthcare by leveraging technology to provide a comprehensive range of services. Its mobile application allows users to connect with hospitals and doctors, schedule appointments, and access medical advice and ratings for healthcare providers. By integrating both online and offline medical services, WeDoctor aspires to serve as a health management organization, facilitating improved healthcare experiences for millions of families. The platform emphasizes a user-friendly approach to healthcare, making essential medical services readily available and efficient.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Shanhu Health is a company focused on advancing digital medicine through the development of clinical application software. It specializes in creating computerized systems that enhance clinical research processes, including interactive response technology, electronic data capture, and clinical trial management systems, all built on cloud technology. By leveraging digital intelligence, Shanhu Health accelerates drug development and offers consultancy services for risk-based monitoring and the implementation of clinical research management systems.

Insight Lifetech is a medical technology company focused on developing and manufacturing innovative solutions for the diagnosis and treatment of cardiovascular diseases. The company has established a comprehensive platform that integrates research and development, manufacturing, and commercialization, facilitating collaboration across its operations. This synergy accelerates product development, enhances cost-efficiency, and fosters innovation. Notably, Insight Lifetech developed the first domestic fractional flow reserve (FFR) system in China, which received approval from the National Medical Products Administration. Through its high-quality medical devices and advanced technologies, the company aims to provide reliable precision in cardiovascular diagnosis and therapy, ultimately enabling physicians to save and improve patients' lives.

OriGynMED provides deep professional resources for the invested companies through its global ecosystem to help the business development of the companies. It is a technology-based medical company.

Virta Health is a San Francisco–based health technology company that specializes in treating type 2 diabetes through an online, physician-supported program. The company combines nutritional biochemistry, data science, and digital tools to deliver on-demand care via a continuous remote care platform, providing physicians and health coaches who guide patients to reduce blood sugar and lose weight without medications or surgery. Founded in 2014, Virta offers a treatment approach aimed at reversing type 2 diabetes and improving related metabolic and cardiovascular health.

Pristyn Care is a healthcare startup focused on transforming day care procedures through advanced surgical care and innovative techniques. Founded by former consultant surgeons from prestigious institutions, along with professionals from the technology and business sectors, the company aims to enhance patient outcomes and streamline the surgical experience. Pristyn Care specializes in advanced laser surgeries across various medical fields, including urology, proctology, ENT, gynecology, laparoscopy, and dermatology. By leveraging cutting-edge technology and implementing efficient operational processes, Pristyn Care seeks to create a comprehensive ecosystem that organizes and optimizes day care procedures, ultimately improving recovery times and overall health for patients.

Dizal Pharmaceutical is a research-driven biotechnology company that specializes in the discovery, development, and commercialization of innovative medicines. The company focuses on creating first-in-class and best-in-class therapeutic solutions, emphasizing the development of groundbreaking drugs. With a commitment to advancing healthcare, Dizal engages in extensive research and development activities, alongside production and sales of its pharmaceutical products. Through its efforts, Dizal aims to contribute significantly to the pharmaceutical industry by delivering effective treatments that address unmet medical needs.

LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapy for cancer treatment. Founded in 2018 and headquartered in New Haven, Connecticut, the company utilizes directed evolution to create novel cytokines that enhance the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor effects in animal models, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. This innovative approach aims to provide patients with more effective immunotherapies, thereby improving their ability to fight cancer.

Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

CERo Therapeutics is a biotechnology company focused on cellular immunotherapy and next-generation engineered T cell therapeutics for cancer. It develops platforms that integrate innate and adaptive immune programs to enhance anti-tumor activity and engage the body's full immune repertoire. The company was incorporated in 2016 and is headquartered in San Francisco, California. Its lead product, CER-1236, is an autologous T-cell therapy targeting a novel tumor antigen, TIM-4 ligand.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

Pristyn Care is a healthcare startup focused on transforming day care procedures through advanced surgical care and innovative techniques. Founded by former consultant surgeons from prestigious institutions, along with professionals from the technology and business sectors, the company aims to enhance patient outcomes and streamline the surgical experience. Pristyn Care specializes in advanced laser surgeries across various medical fields, including urology, proctology, ENT, gynecology, laparoscopy, and dermatology. By leveraging cutting-edge technology and implementing efficient operational processes, Pristyn Care seeks to create a comprehensive ecosystem that organizes and optimizes day care procedures, ultimately improving recovery times and overall health for patients.

Mosaic Wellness is a platform of digital-first health clinics and wellness brands operating in India under a single umbrella. It provides medical consultations, personalized wellness assessments, and a range of wellness products through its digital platform, with specialized offerings for men's and women's health. By linking multiple digital health brands, Mosaic Wellness seeks to help individuals lead healthier, more fulfilling lives through accessible, tailored care and products.

Shanghai Anovent Pharmaceutical Co., Ltd., founded in 2017 and headquartered in Shanghai, China, specializes in the development of high-quality inhalation medicines tailored for hospitals and medical institutions. The company focuses on offering safe and affordable pharmaceutical products, which include both generic and specialized inhalation therapies. By providing these medications, Anovent aims to enhance the quality of medical treatment available to patients in healthcare settings.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Vim Inc., established in 2015 and headquartered in San Francisco, specializes in a healthcare platform that facilitates online services for patients and healthcare providers. The company's core offerings include online appointment scheduling solutions and referral coordination services, aiming to streamline care delivery between patients and medical professionals. Vim connects health plans, patients, and providers across various sizes and systems, with the mission of enhancing affordable, high-quality healthcare through seamless data connectivity within clinical operations at the point of patient care.

Yaoyanshe, established in 2012 and headquartered in Shanghai, China, operates as a Contract Research Organization (CRO) technology platform. It specializes in providing end-to-end services for pharmaceutical research and development, including clinical monitoring, project management, registration affairs, biostatistics, pharmacovigilance, medical affairs, and Site Management Organization (SMO) services. The company's core offering is an application designed to facilitate value sharing and trading within the industry, empowering patients with up-to-date treatment information and enabling professionals to assess creditworthiness, analyze competition, and evaluate sponsor projects more effectively. Yaoyanshe aims to address key industry challenges and enhance the efficiency of pharmaceutical research and development.

Pristyn Care is a healthcare startup focused on transforming day care procedures through advanced surgical care and innovative techniques. Founded by former consultant surgeons from prestigious institutions, along with professionals from the technology and business sectors, the company aims to enhance patient outcomes and streamline the surgical experience. Pristyn Care specializes in advanced laser surgeries across various medical fields, including urology, proctology, ENT, gynecology, laparoscopy, and dermatology. By leveraging cutting-edge technology and implementing efficient operational processes, Pristyn Care seeks to create a comprehensive ecosystem that organizes and optimizes day care procedures, ultimately improving recovery times and overall health for patients.

Yuanxin Huibao is a health insurance technology service provider that specializes in medical insurance for major and chronic diseases. The company focuses on enhancing user experiences by offering comprehensive medical coverage, which includes features such as special drug services, video consultations, welfare drugs, and claims investigations. By integrating these services, Yuanxin Huibao aims to deliver more reliable medical solutions to its users while also providing insurance companies with a one-stop solution for risk control, pricing, and user acquisition.

Biofourmis is a biotechnology company based in Boston, Massachusetts, founded in 2015. It specializes in personalized care and therapies through the use of digital therapeutics. The company develops and delivers clinically validated software-based therapeutics that enhance patient outcomes. Biofourmis has created a predictive health analytics platform that analyzes physiology data gathered from clinical-grade wearables. Utilizing artificial intelligence, this platform integrates and interprets continuous physiological data to identify personalized patterns and predict potential clinical exacerbations. By enabling medical professionals to intervene days before critical events occur, Biofourmis aims to improve patient care and provide cost-effective solutions for healthcare providers.

Tencent Trusted Doctors, a company established in early August 2018 upon the merger of Tencent Doctorwork and Trusted Doctors, is acquiring the start-up in an attempt to create a private healthcare network that provides both online and offline services through the so-called "celebrity effect".

Burning Rock Biotech is a cancer diagnostics company that leverages next-generation sequencing and bioinformatics to guide personalized cancer treatment. It develops and provides a portfolio of tissue- and blood-based, NGS-driven therapy selection tests, including OncoScreen Plus, LungPlasma, ColonCore and HRDCore, and evaluates biomarkers such as microsatellite instability, tumor mutation burden, and NTRK fusions across multiple cancer types, including lung, gastrointestinal, prostate, breast, hematologic, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. The company supports clinical and research use through one-stop services spanning genetic testing and companion diagnostic development, operating through central laboratory and in-hospital models. It collaborates with major pharmaceutical companies on clinical trials and research to advance targeted therapies and diagnostics. Founded in 2014, it is headquartered in Guangzhou, with a Guangzhou laboratory and an R&D center in Shanghai, reflecting its focus on expanding access to precision oncology in China.

Miaoshou Doctor is a healthcare service platform established in 2015 by Tao He and Daoliang Han, headquartered in Beijing. The company focuses on facilitating communication between patients and healthcare professionals, enabling effective management of post-diagnosis outcomes. Its platform empowers doctors to actively monitor their patients' health through ongoing counseling and prescription support, enhancing the overall patient care experience. By streamlining interactions and follow-ups, Miaoshou Doctor aims to improve health outcomes and foster better relationships between patients and their healthcare providers.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

VoxelCloud Inc. is a technology company specializing in cloud computing and artificial intelligence solutions aimed at enhancing the interpretation of medical images and clinical data. Founded in 2015 and headquartered in Los Angeles, California, VoxelCloud develops automated medical image analysis services that assist healthcare practitioners in diagnosing conditions such as lung cancer, diabetic retinopathy, coronary heart disease, and liver disease. Utilizing proprietary algorithms and deep learning techniques, the company provides accurate and timely insights, transforming clinical workflows and enabling evidence-based decision-making. In addition to its Los Angeles headquarters, VoxelCloud maintains offices in Shanghai and Suzhou, China, and has a satellite research and development team in Phoenix, further supporting its commitment to advancing healthcare through innovative technology.

Infervision is a Beijing-based artificial intelligence company specializing in medical imaging diagnosis through advanced deep learning technology and computer vision. The company develops innovative products aimed at enhancing the efficiency and accuracy of cancer diagnosis. Infervision's efforts led to the creation of the world's first artificial intelligence precise healthcare platform, along with intelligent X-ray and CT assisted diagnosis products, which are currently undergoing trials in several prestigious hospitals across China. The company is deeply committed to academic collaboration, partnering with leading institutions in Chinese Radiology to integrate medical science with technology. Infervision has established partnerships with nearly 20 top-tier hospitals, facilitating the seamless integration of medical data, technology, and application scenarios. This unique approach has enabled Infervision to build a comprehensive artificial intelligence computing platform and a precise healthcare intelligence system that supports medical professionals in delivering better diagnostic outcomes with increased efficiency and reduced costs.

Beijing Deep Intelligent Pharma Technology Co., Ltd. specializes in leveraging artificial intelligence and blockchain technology to enhance drug discovery, development, and medical affairs for pharmaceutical companies. Founded in 2017 and based in Beijing, the company offers a range of products, including a multi-language medical machine translation engine, intelligent pharmacovigilance for risk management, and tools for creating multilingual educational materials. Deep Intelligent Pharma also provides AI-enabled solutions for medical writing, document review, and quality control, as well as a patient search ecosystem to facilitate medical and clinical research. Additionally, the company offers intelligent regulatory affairs solutions to streamline drug research and development processes. Operating globally, including in China, the United States, and Japan, Deep Intelligent Pharma aims to improve the efficiency and quality of the pharmaceutical development lifecycle.

Medlinker operates as a social networking platform specifically designed for certified doctors, enabling them to connect with peers and access high-quality medical information. The platform facilitates knowledge sharing among healthcare professionals, allowing users to exchange experiences and insights. It offers various features, including medical quizzes, case mapping, and anonymous social circles, aimed at enhancing collaboration within the medical community. Additionally, Medlinker connects verified doctors with healthcare institutions, pharmaceutical companies, patients, and insurance firms, streamlining the process for patients to book medical appointments and submit inquiries to the medical community. Through these functionalities, Medlinker aims to improve the efficiency of healthcare interactions and support physicians in their professional development.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

MabSpace Biosciences is a biotechnology company established in 2013, specializing in the discovery and development of innovative antibody-based therapeutics aimed at treating cancer and fibrotic diseases affecting the lungs, kidneys, and liver. Located in Biobay Suzhou, a notable biotech incubator in China, the company employs its proprietary immune tolerance breaking technology (IMBT) to generate lead antibodies with diverse epitopes. This technology allows MabSpace to develop therapeutics that target various components of the tumor microenvironment, enhancing treatment efficacy. The company has established multiple partnerships for antibody discovery and co-development, and it has advanced its lead antibody program, which includes a potentially best-in-class anti-PD-L1 antibody known for its unique pH-dependent binding and recycling properties. Additionally, MabSpace has developed a panel of second-generation immuno-oncology antibodies that facilitate the exploration of combination therapeutic interventions alongside its PD-L1 antibody.

CStone Pharmaceuticals, founded in 2015, focuses on developing and commercializing innovative immunotherapy and precision treatment drugs for cancer patients worldwide. Its pipeline comprises over a dozen candidates targeting various indications, with immuno-oncology at its core.

Synyi is a provider of AI-powered healthcare data platforms for medical institutions and regulatory agencies, specializing in medical big data management systems, intelligent diagnostic tools, digital healthcare applications, and EEG-based case generation models that support clinical research, enhance operational efficiency, and enable digital transformation across the healthcare ecosystem. The company benefits from a highly qualified core team drawn from leading universities and international organizations in artificial intelligence, medicine, and medical informatics, whose technical achievements have been applied to national and municipal projects and who have published extensively in international journals and spoken at major medical conferences.